Tag: advanced hepatocellular carcinoma

May 13, 2019 Off

Lilly gets fifth FDA approval for Cyramza

By Dino Mustafić

Eli Lilly’s Cyramza got its fifth FDA approval for in an advanced or metastatic cancer – this one for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL).